Literature DB >> 7259960

A case-control study of the possible association between oral contraceptives and malignant melanoma.

S A Adam, J K Sheaves, N H Wright, G Mosser, R W Harris, M P Vessey.   

Abstract

In a case-control study, we investigated 169 women aged 15-49 years with malignant melanoma notified to the Oxford and South Western cancer registries during the years 1971-1976, together with 507 matched controls. Data about medical, reproductive, drug and smoking histories were obtained both by reviewing general practitioner (GP) records and from the women themselves by postal questionnaires. There was no significant evidence of any overall increase in the risk of melanoma in oral contraceptive (OC) users (data from GP records-ever use vs never use, relative risk (RR) 1.34, 95% confidence limits 0.92-1.96; corresponding data from postal questionnaires-RR 1.13, limits 0.73-1.75). However, although not significant, the risk estimated from data in the postal questionnaires was higher in women who had used OCs for 5 years or more (use greater than or equal to 5 years vs never use, RR 1.57, limits 0.83-3.03). Previously demonstrated risk factors for melanoma, such as fair skin, blond or red hair and Celtic origin were found to be commoner in the cases than in the controls. Data from the Oxford/Family Planning Association contraceptive study were also examined. Unexpectedly there was a strong suggestion of a negative association between OC use and melanoma risk, but the analysis was based on only 12 women with the disease.

Entities:  

Keywords:  Age Factors; Biology; Cancer; Case Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Methods--side effects; Contraceptive Methods--statistics; Control Groups; Data Analysis; Dermatological Effects; Developed Countries; Diseases; England; Europe; Family Planning; Neoplasms; Northern Europe; Oral Contraceptives--side effects; Oral Contraceptives--statistics; Physiology; Questionnaires; Records; Research Methodology; Studies; Study Design; United Kingdom

Mesh:

Substances:

Year:  1981        PMID: 7259960      PMCID: PMC2010646          DOI: 10.1038/bjc.1981.145

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

Review 1.  Current evidence about the causes of malignant melanoma.

Authors:  J A Lee
Journal:  Prog Clin Cancer       Date:  1975

2.  Recent data on the epidemiology of malignant melanoma.

Authors:  J M Elwood; J A Lee
Journal:  Semin Oncol       Date:  1975-06       Impact factor: 4.929

3.  A long-term follow-up study of women using different methods of contraception--an interim report.

Authors:  M Vessey; R Doll; R Peto; B Johnson; P Wiggins
Journal:  J Biosoc Sci       Date:  1976-10

4.  Incidence of malignant melanoma of the skin in the five Nordic countries: significance of solar radiation.

Authors:  K Magnus
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

Review 5.  Cutaneous side effects of oral contraceptives.

Authors:  J E Jelinek
Journal:  Arch Dermatol       Date:  1970-02

6.  Malignant melanoma. A controlled study of possibly associated factors.

Authors:  G A Gellin; A W Kopf; L Garfinkel
Journal:  Arch Dermatol       Date:  1969-01

7.  Genetic predisposition to melanoma and other skin cancers in Australians.

Authors:  M M Brown; C A Sharpe; D S Macmillan; V J McGovern
Journal:  Med J Aust       Date:  1971-04-17       Impact factor: 7.738

8.  On the causes of melanomas.

Authors:  J J Nordlund; A B Lerner
Journal:  Am J Pathol       Date:  1977-11       Impact factor: 4.307

9.  Chloasma and oral contraceptives.

Authors:  R Carruthers
Journal:  Med J Aust       Date:  1966-07-02       Impact factor: 7.738

10.  Oestrogen receptors in human malignant melanoma.

Authors:  R I Fisher; J P Neifeld; M E Lippman
Journal:  Lancet       Date:  1976-08-14       Impact factor: 79.321

View more
  28 in total

1.  Indoor tanning facility density in eighty U.S. cities.

Authors:  Richard C Palmer; Joni A Mayer; Susan I Woodruff; Laura Eckhardt; James F Sallis
Journal:  J Community Health       Date:  2002-06

2.  Examination of the efficacy of an appearance-focused intervention to reduce UV exposure.

Authors:  Joel J Hillhouse; Rob Turrisi
Journal:  J Behav Med       Date:  2002-08

3.  Indoor tanning and risk of melanoma: a case-control study in a highly exposed population.

Authors:  DeAnn Lazovich; Rachel Isaksson Vogel; Marianne Berwick; Martin A Weinstock; Kristin E Anderson; Erin M Warshaw
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-26       Impact factor: 4.254

Review 4.  Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill?

Authors:  H Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Critique of the International Agency for Research on Cancer's meta-analyses of the association of sunbed use with risk of cutaneous malignant melanoma.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2009-11

6.  Age at first birth and melanoma risk: a meta-analysis.

Authors:  Zhengyong Li; Mingjin Gu; Ying Cen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

7.  Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma.

Authors:  A J Swerdlow; J S English; R M MacKie; C J O'Doherty; J A Hunter; J Clark; D J Hole
Journal:  BMJ       Date:  1988-09-10

Review 8.  Cutaneous malignant melanoma and ultraviolet radiation: a review.

Authors:  J Longstreth
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

9.  Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: Western Canada Melanoma Study.

Authors:  J M Elwood; R P Gallagher; G B Hill; J J Spinelli; J C Pearson; W Threlfall
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

Review 10.  The relationship between oral contraceptive use, cancer and vascular disease.

Authors:  C La Vecchia; S Franceschi; P Bruzzi; F Parazzini; P Boyle
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.